[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cervical-cancer-squamous-cell\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cervical-cancer-squamous-cell":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100642492","hypofractionated-radiotherapy-in-cervical-cancer-100642492",false,"NCT07625943","HYPOfractionated RadioTherapy in Cervical Cancer","Hypofractionated Radiotherapy in Cervical Cancer: A Non-inferiority Randomized Controlled Trial","HYPORT-CC","Inclusion Criteria:\n\nFemale participants aged 18 to 65 years.\n\nHistopathologically confirmed cervical cancer.\n\nFIGO stage IB3 to IIIC1.\n\nSuitable for definitive concurrent chemoradiation.\n\nECOG performance status 0 to 2.\n\nAdequate hematological, renal, and hepatic function.\n\nAble and willing to provide informed consent.\n\nExclusion Criteria:\n\nECOG performance status 3 or higher.\n\nFIGO stage IIIC2, IVA, or IVB.\n\nPrior pelvic radiotherapy or prior chemotherapy for cervical cancer.\n\nInflammatory bowel disease.\n\nHydronephrosis.\n\nPregnancy.\n\nSynchronous malignancy.\n\nAny serious medical condition that would interfere with protocol treatment or follow-up.","FEMALE","18 Years","65 Years",{"count":21,"type":22},396,"ESTIMATED","INTERVENTIONAL",[25],"NA","The study is a prospective, randomized, non-inferiority clinical trial which will test whether a short course of radiation treatment (hypofractionation) for cervical cancer works as well as the standard longer course. Cervical cancer is one of the most common cancers in women in India, and many patients have trouble completing treatment because it takes several weeks and requires many hospital visits.\n\nIn this trial, females with locally advanced cervical cancer will be randomly assigned to one of two treatment groups. One group will receive the standard radiation schedule with External Beam RadioTherapy (EBRT) over about 5 weeks, weekly cisplatin chemotherapy, and brachytherapy. The other group will receive a shorter, hypofractionated external beam radiotherapy schedule over about 3 weeks, the same chemotherapy, and brachytherapy.\n\nResearchers will compare the two groups to see whether the hypofractionated schedule is non-inferior to the standard radiation therapy schedule. The main outcomes will be tumor control in the pelvis, side effects, survival, and quality of life. If the hypofractionated schedule meets the non-inferiority limit, it could reduce treatment time, improve patient convenience, and help more people receive treatment in busy cancer centers in emerging countries.",[28,29],"Cervical Cancer Squamous Cell","Cervical Cancer",[31,32,33,34,35],"cervical cancer","chemoradiation","hypofractionation","brachytherapy","external beam radiotherapy","RECRUITING","2026-06-12",{"date":39,"type":40},"2026-06-16","ACTUAL",{"date":42,"type":40},"2026-01-15",{"date":44,"type":22},"2030-01-30",{"name":46,"class":47},"All India Institute of Medical Sciences","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":60,"conditions":61,"keywords":65,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":4},"100603797","phase-2-ql1706-in-patients-with-recurrent-and-metastatic-cervical-cancer-resistant-to-prior-pd-1pd-l1-antibody-therapy-100603797","NCT07141186","QL1706 in Patients With Recurrent and Metastatic Cervical Cancer Resistant to Prior PD-1\u002FPD-L1 Antibody Therapy","A Prospective, Single-Arm, Phase II Trial of QL1706 in Patients With Recurrent and\u002For Metastatic Cervical Cancer Who Had Developed Resistance to Prior PD-1\u002FPD-L1 Antibody Therapy","Inclusion Criteria:\n\n1. Patients with recurrent\u002Fmetastatic cervical cancer who previously experienced failure of PD-1 blockade therapy;\n2. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;\n3. Life expectancy ≥3 months;\n4. At least one measurable lesion per RECIST v1.1:\n\n   Non-lymph node lesion: Longest diameter ≥10 mm Lymph node lesion: Short-axis diameter ≥15 mm Note: Previously irradiated lesions must be outside radiation fields or demonstrate progression post-radiation.\n5. Adequate organ function within 14 days prior to treatment:\n\n   1. Absolute neutrophil count (ANC) ≥1.0×10⁹\u002FL\n   2. Hemoglobin ≥60 g\u002FL\n   3. Platelet count ≥50×10⁹\u002FL\n   4. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3×ULN (≤5×ULN for hepatic metastasis)\n   5. Serum creatinine ≤2×ULN\n6. Reproductive requirements:\n\n   1. Non-childbearing potential (surgically sterilized or postmenopausal) OR\n   2. Women of childbearing potential:\n\n   Negative serum pregnancy test within 7 days prior to enrollment Commitment to use double-barrier contraception throughout the study and for 180 days post-treatment\n7. Ability to comply with scheduled visits, treatment plans, and laboratory tests;\n8. Voluntarily signed written informed consent.\n\nExclusion Criteria:\n\n1. Prior treatment with anti-PD-1\u002FCTLA-4 bispecific antibodies;\n2. Active autoimmune disease requiring systemic control with corticosteroids (≥10 mg\u002Fday prednisone equivalent) or immunosuppressants within 14 days prior to enrollment;\n3. Clinically significant cardiovascular\u002Fcerebrovascular events within 6 months prior to treatment, including:\n\n   1. Acute myocardial infarction\n   2. Unstable angina\n   3. Cerebrovascular accident\n   4. Symptomatic arterial\u002Fvenous thrombosis or ischemic cardiomyopathy\n   5. Clinically significant ventricular arrhythmias (sustained VT, VF, torsades de pointes)\n   6. NYHA Class III\u002FIV heart failure\n   7. QTcF ≥480 ms or congenital long QT syndrome\n   8. LVEF \\\u003C50% or severe wall motion abnormality per echocardiography\n   9. Uncontrolled hypertension (SBP \\>160 mmHg or DBP \\>100 mmHg)\n   10. Other clinically significant arrhythmias (e.g., third-degree AV block);\n4. Uncontrolled comorbidities potentially affecting protocol compliance:\n\n   * Severe respiratory diseases (ILD, severe asthma)\n   * Active infections:\n\n     * HBV (HBsAg+ AND HBV-DNA \\>500 IU\u002FmL)\n     * HCV (HCV-Ab+ AND HCV-RNA+)\n     * HIV-Ab+\n     * Active TB or systemic infections requiring treatment ≤14 days\n   * GI perforation\u002Ffistula ≤6 months (exceptions: resolved surgically)\n   * Clinically significant bleeding ≤1 month (hematemesis, hemoptysis, etc.)\n   * Active diverticulitis, abdominal abscess, or bowel obstruction;\n5. Other malignancies within 3 years (excluding cured BCC, superficial bladder Ca, DCIS, or papillary thyroid Ca);\n6. Known immunodeficiency disorders;\n7. History of allogeneic hematopoietic stem cell or solid organ transplantation (excluding corneal grafts);\n8. Systemic infections requiring IV antibiotics \\>7 days within 2 weeks prior to treatment;\n9. Administration of live attenuated vaccines within 4 weeks before\u002Fafter treatment;\n10. Pregnancy or lactation;\n11. Investigator-assessed ineligibility;\n12. Concurrent participation in other clinical trials.",{"count":57,"type":22},50,[59],"PHASE2","To explore the efficacy and safety of administrating QL1706 in patients with recurrent and\u002For metastatic cervical cancer who had developed resistance to prior PD-1\u002FPD-L1 antibody therapies.",[29,62,63,64,28],"Cervical Cancer Metastatic","Cervical Cancer Recurrent","Cervical Adenocarcinoma",[31,66,67,68,69],"immunotherapy","PD-1\u002FCTLA-4 bispecific antibody","QL1706","PD-1 resistant","NOT_YET_RECRUITING","2025-08-25",{"date":73,"type":40},"2025-08-26",{"date":75,"type":22},"2025-10-01",{"date":77,"type":22},"2030-10-01",{"name":79,"class":47},"Tianjin Medical University Cancer Institute and Hospital"]